Gilead Sciences, Inc. (OQ:GILD)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 333 LAKESIDE DR
FOSTER CITY CA 94404
Tel: N/A
Website: https://www.gilead.com
IR: See website
<
Key People
Daniel P O'Day
Chairman of the Board, Chief Executive Officer
Andrew D. Dickinson
Chief Financial Officer
Deborah H. Telman
Executive Vice President - Corporate Affairs, General Counsel
Johanna Mercier
Chief Commercial Officer
Merdad V. Parsey
Chief Medical Officer
 
Business Overview
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
Financial Overview
For the three months ended 31 March 2024, Gilead Sciences, Inc. revenues increased 5% to $6.69B. Net loss applicable to common stockholders totaled $4.17B vs. income of $1.01B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Acquired in-process research and develop increase from $481M to $4.13B (expense).
Employees: 18,000 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $27,450M as of Mar 31, 2024
EBITDA (TTM): $11,631M as of Mar 31, 2024
Net annual income (TTM): $484.00M as of Mar 31, 2024
Free cash flow (TTM): $5,166M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 1,246,000,000 as of Mar 31, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.